These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 17932395)

  • 1. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
    Warbey VS; Ferner RE; Dunn JT; Calonje E; O'Doherty MJ
    Eur J Nucl Med Mol Imaging; 2009 May; 36(5):751-7. PubMed ID: 19142634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
    Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
    J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
    Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
    J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1.
    Shahid KR; Amrami KK; Esther RJ; Lowe VJ; Spinner RJ
    J Surg Orthop Adv; 2011; 20(2):132-5. PubMed ID: 21838076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
    Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
    Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [
    Azizi AA; Slavc I; Theisen BE; Rausch I; Weber M; Happak W; Aszmann O; Hojreh A; Peyrl A; Amann G; Benkoe TM; Wadsak W; Kasprian G; Staudenherz A; Hacker M; Traub-Weidinger T
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28771999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between benign and malignant peripheral nerve sheath tumors in NF1.
    Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
    Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of
    Cook GJR; Lovat E; Siddique M; Goh V; Ferner R; Warbey VS
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1845-1852. PubMed ID: 28589254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.
    Salamon J; Derlin T; Bannas P; Busch JD; Herrmann J; Bockhorn M; Hagel C; Friedrich RE; Adam G; Mautner VF
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):685-92. PubMed ID: 23232507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
    Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T
    Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.
    Nishida Y; Ikuta K; Ito S; Urakawa H; Sakai T; Koike H; Ito K; Imagama S
    Cancer Sci; 2021 Mar; 112(3):1114-1122. PubMed ID: 33415792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
    Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Derlin T; Tornquist K; Münster S; Apostolova I; Hagel C; Friedrich RE; Wedegärtner U; Mautner VF
    Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
    Brahmi M; Thiesse P; Ranchere D; Mognetti T; Pinson S; Renard C; Decouvelaere AV; Blay JY; Combemale P
    PLoS One; 2015; 10(10):e0138386. PubMed ID: 26445379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1.
    Moharir M; London K; Howman-Giles R; North K
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1309-17. PubMed ID: 20179923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
    Salamon J; Mautner VF; Adam G; Derlin T
    Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of [
    Tovmassian D; Abdul Razak M; London K
    Int J Surg Oncol; 2016; 2016():6162182. PubMed ID: 28058117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.